NVAX

Novavax (NVAX) has been heavily searched by investors recently, outperforming the S&P 500 by 4.8% over the past month. However, the company faces significant headwinds with revenue declining 66.4% for the current fiscal year and 9.5% for the next year. While the company has beaten earnings and revenue estimates in the trailing four quarters, it carries a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

Novavax stock declined 3.91% to $10.82, underperforming the broader market's gains. While the vaccine maker gained 11.38% over the past month, upcoming earnings expectations show challenges ahead with anticipated EPS of -$0.33 and revenue declining 28.15% year-over-year. The company holds a Zacks Rank #3 (Hold) rating.

Novavax stock closed at $12.82, up 1.26% and outperforming the broader market decline. The vaccine maker has surged 32.01% over the past month.

However, upcoming earnings show mixed signals: EPS expected to improve 46.77% YoY to -$0.33, but revenue projected to fall 28.15% to $50.61 million. Full-year estimates show significant declines with -114.73% EPS change and -66.4% revenue decline. The stock holds a Zacks Rank #3 (Hold) rating.